---
title: "Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295931319.md"
description: "Allarity Therapeutics reported a Q2 FY26 net loss of $3.41 million, widening from $2.32 million previously, with EPS at $0.21. However, operating losses narrowed to $2.67 million due to significant reductions in R&D and G&A expenses. Cash reserves increased to $26.9 million. The company completed a Phase 3-ready API manufacturing campaign for stenoparib and secured a USPTO patent for its companion diagnostic through April 2042."
datetime: "2026-08-14T12:01:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295931319.md)
  - [en](https://longbridge.com/en/news/295931319.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295931319.md)
---

# Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million

-   Allarity Therapeutics posted a Q2 net loss of USD 3.41 million, widening from USD 2.32 million a year earlier; loss per share rose to USD 0.21. \* Operating loss narrowed to USD 2.67 million from USD 4.13 million, as R&D fell 42% to USD 1.35 million and G&A dropped 26.82% to USD 1.33 million. \* Cash and restricted cash climbed to USD 26.9 million at June 30, up from USD 14.7 million a year earlier; operating cash outflow was USD 2.6 million. \* Completed a Phase 3-ready stenoparib API manufacturing campaign in July, with all payments booked as prepaid expenses and no additional cash outlays expected. \* USPTO granted a U.S. patent covering the stenoparib DRP companion diagnostic through April 2042; CLIA certification secured for its in-house DRP testing lab. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED1001257591) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)

## Related News & Research

- [Allarity Therapeutics secures CLIA certification for in-house DRP testing lab](https://longbridge.com/en/news/291945556.md)
- [Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress](https://longbridge.com/en/news/290433741.md)
- [Wagyu.xyz Reports $700 Million in Monero Order Flow and Opens Its Public API to Third-Party Operators](https://longbridge.com/en/news/296087696.md)
- [How Comcast’s API‑Driven Global Connectivity Push Could Reshape Its Convergence Story for Investors (CMCSA)](https://longbridge.com/en/news/296173834.md)
- [Dr. Reddy’s API and Services CEO Deepak Sapra resigns, set to exit in November](https://longbridge.com/en/news/295811050.md)